Clinical ResearchClinical TrialCorrelates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide: Observations From the PROTECT–TIMI-30 Trial
Clinical Trial
Under an Elsevier user license
open archive
Abbreviations and Acronyms
ACS
acute coronary syndrome
ACT
activated clotting time
Cr
creatinine
CrCl
creatinine clearance
GFR
glomerular filtration rate
GPIIb/IIIa
glycoprotein IIb/IIIa receptor
NSTEACS
non–ST-segment elevation acute coronary syndrome
PCI
percutaneous coronary intervention
UFH
unfractionated heparin
Cited by (0)
Supported in part by a grant from Millennium Pharmaceuticals, Cambridge, Massachusetts, and Schering-Plough Research Institute, Kenilworth, New Jersey.
- 1
Dr. Cohen has received grant support from the Medicines Company, Millennium Pharmaceuticals, and Schering-Plough.
- 2
Dr. Peterson has received grant support from Schering-Plough and Millennium Pharmaceuticals.
- 3
Dr. Herrmann has received research funding from Millennium Pharmaceuticals and has served as a consultant for Millennium Pharmaceuticals.
- 4
Dr. Palabrica is an employee of Millennium Pharmaceuticals.
- 5
Dr. Gibson has received grant support and honoraria and has served as a consultant for the Medicines Company, Millennium Pharmaceuticals, and Schering-Plough.
Copyright © 2006 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.